Foundation Medicine Receives Accreditation from the College of American Pathologists
CAMBRIDGE, Mass., March 4, 2013 - Foundation Medicine, Inc. today announced that it has received accreditation from the Commission on Laboratory Accreditation of the College of American Pathologists (CAP) based on the results of a recent on-site laboratory inspection. The U.S. federal government recognizes the CAP Laboratory Accreditation Program as being equal-to or more-stringent-than the government's own inspection program.
"Foundation Medicine and CAP share a driving commitment to laboratory quality, patient safety and best-in-class care," said Kevin Krenitsky, M.D., chief commercial officer and senior vice president, international strategy of Foundation Medicine. "Our team has turned a highly complex and advanced clinical analysis into a standardized, routine laboratory procedure that yields actionable genomic information and often reveals new treatment options for oncologists and their patients. It is gratifying to see the persistence and dedication of our team recognized by this highly regarded organization."
During the CAP inspection process, designed to ensure the highest standard of care for all patients, inspectors examine the laboratory's records and quality control procedures. CAP inspectors also examine staff qualifications, laboratory equipment, and the facilities' safety program and record, as well as the overall laboratory management.
About the College of American Pathologists
The College of American Pathologists (CAP) is a medical society with more than 18,000 physician members who specialize in diagnosing disease and it is the worldwide leader in laboratory quality assurance, celebrating more than 50 years as the gold standard in laboratory accreditation. The CAP is the world's largest organization composed exclusively of board-certified pathologists. The CAP advocates accountable, high-quality, and cost-effective patient care. The CAP was recognized by the Chicago Tribune as one of the city's 2012 Top Workplaces. More information about the CAP can be found at www.cap.org.
About Foundation Medicine
Foundation Medicine® is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's initial clinical assay, FoundationOne™, is a fully informative genomic profile to identify a patient's individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® is a registered trademark, and FoundationOneTM is a trademark, of Foundation Medicine, Inc.
Pure Communications, Inc.